What was the overall market valuation of the US pneumoconiosis market in 2024?

The overall market valuation was $386.4 Million in 2024. Read More

What is the projected market valuation for the US pneumoconiosis market by 2035?

The projected valuation for 2035 is $525.2 Million. Read More

What is the expected CAGR for the US pneumoconiosis market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 2.83%. Read More

Which companies are considered key players in the US pneumoconiosis market?

Key players include Bristol-Myers Squibb, Pfizer, Novartis, Roche, Merck & Co., GlaxoSmithKline, AstraZeneca, Johnson & Johnson, and Sanofi. Read More

What are the market segments for the US pneumoconiosis market?

Market segments include Type, Diagnostic Method, Treatment Type, and End User. Read More

What was the valuation for Asbestosis in the US pneumoconiosis market in 2024?

The valuation for Asbestosis was between $80.0 Million and $110.0 Million in 2024. Read More

How much is projected for the treatment type 'Medications' in the US pneumoconiosis market by 2035?

The projected valuation for 'Medications' is between $150.0 Million and $200.0 Million by 2035. Read More

What is the valuation range for CT Scans in the US pneumoconiosis market?

The valuation range for CT Scans is between $120.0 Million and $160.0 Million. Read More

What is the expected valuation for hospitals as an end user in the US pneumoconiosis market by 2035?

The expected valuation for hospitals is between $200.0 Million and $270.0 Million by 2035. Read More

What was the valuation for Pulmonary Rehabilitation in the US pneumoconiosis market in 2024?

The valuation for Pulmonary Rehabilitation was between $136.4 Million and $195.2 Million in 2024. Read More

US Pneumoconiosis Market

ID: MRFR/Pharma/18469-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026

US Pneumoconiosis Market Research Report By Type of Pneumoconiosis (Asbestosis, Silicosis, Coal Workers' Pneumoconiosis, Berylliosis), By Diagnostic Method (Chest X-ray, CT Scan, Lung Function Tests, Bronchoscopy), By Treatment Type (Medications, Surgery, Pulmonary Rehabilitation) and By End User (Hospitals, Clinics, Rehabilitation Centers) - Growth & Industry Forecast 2025 To 2035

US Pneumoconiosis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)2.83%

2024 Market Size$ 386.4 Million

2025 Market Size$ 397.34 Million

2035 Market Size$ 525.2 Million

Key Players

Bristol-Myers Squibb

Pfizer

Novartis

Roche

Merck & Co.

GlaxoSmithKline

Trends

Regulatory Changes and Compliance
Advancements in Diagnostic Technologies
Focus on Research and Development

Opportunities

Enhanced Regulatory Frameworks
Government Initiatives and Funding
Technological Innovations in Treatment

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Type (USD Million)
  1. 4.1.1 Asbestosis
  2. 4.1.2 Silicosis
  3. 4.1.3 Coal Workers' Pneumoconiosis
  4. 4.1.4 Berylliosis
2. 4.2 Chemicals and Materials, BY Diagnostic Method (USD Million)
  1. 4.2.1 Chest X-ray
  2. 4.2.2 CT Scan
  3. 4.2.3 Lung Function Tests
  4. 4.2.4 Bronchoscopy
3. 4.3 Chemicals and Materials, BY Treatment Type (USD Million)
  1. 4.3.1 Medications
  2. 4.3.2 Surgery
  3. 4.3.3 Pulmonary Rehabilitation
4. 4.4 Chemicals and Materials, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Rehabilitation Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Roche (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GlaxoSmithKline (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSTIC METHOD
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY DIAGNOSTIC METHOD, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US Pneumoconiosis Market Segmentation

US Pneumoconiosis Market By Type (USD Million, 2025-2035)

Asbestosis
Silicosis
Coal Workers' Pneumoconiosis
Berylliosis

US Pneumoconiosis Market By Diagnostic Method (USD Million, 2025-2035)

Chest X-ray
CT Scan
Lung Function Tests
Bronchoscopy

US Pneumoconiosis Market By Treatment Type (USD Million, 2025-2035)

Medications
Surgery
Pulmonary Rehabilitation

US Pneumoconiosis Market By End User (USD Million, 2025-2035)

Hospitals
Clinics
Rehabilitation Centers

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”